Core Insights - 420 Investor, launched in 2013, has transitioned to Seeking Alpha, continuing its focus on cannabis stocks and providing extensive coverage of the sector [1] - Alan Brochstein, a pioneer in cannabis investment analysis, has been managing 420 Investor and offers a range of resources including model portfolios, videos, and earnings report analyses [1] Company Overview - 420 Investor has been a significant player in the cannabis investment space, providing insights and resources for investors interested in publicly-traded cannabis stocks since its inception [1] - The service includes features such as a model portfolio, weekly videos, summary pieces, a monthly newsletter, and a chat function for investor inquiries [1] Industry Context - The cannabis industry has seen increased interest and investment opportunities, particularly following the legalization of adult-use cannabis in Colorado [1] - The presence of large REIT ETFs, such as iShares U.S. Real Estate ETF and Vanguard Real Estate, indicates a growing interest in real estate investments related to the cannabis sector [1]

Core Insights - The article discusses the launch and evolution of the 420 Investor service, which focuses on cannabis stocks and has transitioned to Seeking Alpha in 2023 [1] - Alan Brochstein, a prominent figure in cannabis investment, has been involved in the industry since 2013 and provides extensive coverage of cannabis stocks through various formats [1] Group 1: Company Overview - 420 Investor was established in 2013, coinciding with Colorado's legalization of cannabis for adult use [1] - The service includes model portfolios, videos, and written materials aimed at educating investors about cannabis stocks [1] - Alan Brochstein is the managing partner of New Cannabis Ventures, which has been providing financial information in the cannabis sector since 2015 [1] Group 2: Investment Features - The investing group closely monitors 20 cannabis stocks, providing timely investment news, earnings report previews, and post-report analyses [1] - Additional features of the group include a model portfolio, 10 weekly videos with chart analysis, three weekly summary pieces, a monthly newsletter, and a chat function for investor inquiries [1] Group 3: Market Context - The article mentions several large REIT ETFs that are tracked, including the iShares U.S. Real Estate ETF (IYR), Real Estate Select Sector SPDR® Fund ETF (XLRE), and Vanguard Real Estate [1]

Industry Overview - The cannabis market was valued at $43.72 billion in 2022 and is projected to reach $444.34 billion by 2030, reflecting a CAGR of 34.03% [1] - Global marijuana legalization is gaining momentum, driven by the recognition of its medicinal value and therapeutic uses [1] Company Performance Tilray Brands (TLRY) - Tilray's shares surged 105.5% over the past six months, outperforming Cresco Labs, which gained only 0.3% [4] - In the fiscal first quarter, Tilray's Canadian cannabis revenues rose 4% year over year to $51 million, supported by significant cultivation capacity of approximately 5 million square feet and 210 metric tons of cannabis in production [10] - The company is expanding its medical cannabis footprint in Europe, with plans to triple its German distribution footprint by fiscal 2026 [5][8] - Tilray's international expansion includes a joint venture in Panama and a partnership in Italy to broaden the availability of its medical cannabis extracts [6][7] - The company is also innovating with new product offerings, such as its first medical cannabis edible in Australia [7] Cresco Labs (CRLBF) - Cresco's shares have gained 0.3% over the past six months, indicating slower growth compared to Tilray [4] - The company launched its flagship Cresco-branded flower in Germany, marking its entry into the EU market, which is one of the fastest-growing regulated cannabis markets [12] - Cresco has partnered with a EU GMP-certified manufacturer in Portugal to produce signature flower SKUs, ensuring compliance with European quality standards [13] - Domestically, Cresco holds leading market shares in key states but faces challenges from a tightly regulated and price-compressed market, with revenues declining year over year [15][16] Valuation Comparison - Tilray is trading at a forward 12-month price-to-sales (P/S) ratio of 1.21, above its median of 0.99, while Cresco's forward sales multiple is 0.38, below its one-year median of 0.58 [18] - For fiscal 2026, Tilray's projected loss per share is 5 cents, while Cresco's is projected at 14 cents [21][22] Strategic Positioning - Tilray's established international infrastructure and diversified strategy position it well for capturing long-term value as global cannabis markets evolve [23] - Cresco is taking initial steps into international markets while maintaining solid positions in limited-license U.S. states, using partnerships to mitigate domestic volatility [24]

Core Insights - cbdMD, Inc. expects year-over-year net sales to remain in line with the prior year, with quarterly net sales projected to increase between 3% and 5% [1] - The company has reported preliminary financial results for the fourth quarter of fiscal 2025, indicating a positive trend in revenue growth compared to peers [2] Financial Performance - Net sales revenue for fiscal 2025 is expected to range between $19.1 million and $19.3 million, a slight decrease from $19.5 million in fiscal 2024 [6] - For the fourth quarter of fiscal 2025, net sales revenue is anticipated to be between $4.7 million and $4.9 million, compared to $4.6 million in the same quarter of fiscal 2024 [6] - The expected net loss for fiscal 2025 is projected to improve from $3.7 million to a range of $1.9 million to $2.1 million [6] Strategic Actions - The company has taken decisive actions to strengthen its business model and create a stable foundation for long-term growth, resulting in positive revenue growth despite industry challenges [2] - cbdMD's management emphasizes disciplined cost management and a focus on profitable growth as key drivers for continued earnings improvement in fiscal 2025 [2] Product Offerings - cbdMD offers a comprehensive line of domestically produced, THC-free CBD products, including its Herbal Oasis brand of THC seltzers and Paw CBD brand for pets [3]

Core Viewpoint - Chicago Atlantic BDC, Inc. is actively participating in the Noble Capital Markets Inc.'s 21st Annual Emerging Growth Equity Conference, indicating its commitment to engaging with investors and showcasing its business strategy focused on the cannabis industry [1][2]. Company Overview - Chicago Atlantic BDC, Inc. is a specialty finance company regulated as a business development company under the Investment Company Act of 1940, aiming to maximize risk-adjusted returns for its stockholders [5]. - The company's investment strategy primarily involves direct loans to privately held middle-market companies, with a significant focus on the cannabis sector [5]. Conference Participation - The company will host one-on-one meetings with investors and present on December 3, 2025, at 3:00 PM ET [2]. - A high-definition video webcast of the presentation will be available the following day on the company's website and other platforms, ensuring broad accessibility for investors [3]. Investor Relations - Investors interested in scheduling meetings with the company's management can contact NobleCon representatives or the company's investor relations team [4].

Vext Science, Inc. (OTC:VEXTF) reported an earnings per share (EPS) of -$0.01, missing the estimated EPS.The company generated a revenue of $12.67 million, with a 41% increase compared to the same period last year.Vext's strategic expansion in Ohio aims to reach the state's dispensary license cap by 2026, positioning the company for future growth.Vext Science, Inc. (OTC:VEXTF) is a U.S.-based cannabis operator with operations in Arizona and Ohio. The company focuses on expanding its retail presence and capi ...

Core Insights - Vext Science, Inc. reported financial results for Q3 2025, correcting previous inaccuracies in EBITDA and Adjusted EBITDA figures [2][3] - The company achieved a revenue of $12.7 million, representing a 41% year-over-year increase, driven by expanded operations in Ohio and stable performance in Arizona [4][7] - Year-to-date operating cash flow reached $8.5 million, a significant improvement compared to $(0.7) million in the same period last year [7] Financial Performance - Corrected Q3 2025 financial results include: - Revenue: $12,670,000 - EBITDA: $1,828,000 - Adjusted EBITDA: $1,625,000 - Adjusted EBITDA Margin: 12.8% [5][14] - Comparison with previous quarters: - Q2 2025 Revenue: $13,407,000; EBITDA: $5,263,000; Adjusted EBITDA: $4,077,000; Adjusted EBITDA Margin: 30% [5][14] - Q3 2024 Revenue: $8,987,000; EBITDA: $1,925,000; Adjusted EBITDA: $2,873,000; Adjusted EBITDA Margin: 32% [5][14] Operational Highlights - The company expanded its retail footprint in Ohio to five locations, with plans to reach a total of eight dispensaries by 2026 [6][7] - Vext's operations in Arizona continued to outperform state averages on a per-store basis, maintaining steady performance despite market challenges [6][7] - Management expressed confidence in sustaining operational momentum and improving cash flow in Q4 2025 [6][8] Recent Developments - On September 17, 2025, Vext received regulatory approval to transfer ownership of the Herbal Wellness Center dispensary in Portsmouth, Ohio, completing the transfer on October 1, 2025 [9]

Core Insights - Vext Science, Inc. reported a revenue of $12.7 million for Q3 2025, representing a 41% increase year-over-year, driven by expanded retail operations in Ohio and resilient performance in Arizona [4][5] - Year-to-date operating cash flow reached $8.5 million, a significant improvement compared to $(0.7) million in the same period last year [5] - The company is on track to expand its retail footprint in Ohio, aiming to reach the state dispensary license cap of eight by 2026 [5][18] Financial Performance - Q3 2025 revenue was $12,670,000, compared to $13,407,000 in Q2 2025 and $8,987,000 in Q3 2024 [3] - EBITDA for Q3 2025 was $2,315,000, down from $5,263,000 in Q2 2025 but up from $1,925,000 in Q3 2024 [3][10] - Adjusted EBITDA for Q3 2025 was $2,112,000, with an adjusted EBITDA margin of 16.7%, compared to 30% in Q2 2025 and 32% in Q3 2024 [3][10] Operational Highlights - The company has strengthened its retail presence in Ohio, consolidating operations to five locations and planning for three additional dispensaries [5][18] - Vext's operational discipline has allowed it to outperform state averages in Arizona, maintaining steady performance despite broader market declines [4] - The company expects continued operational momentum and improved cash flow in Q4 2025 as it addresses inventory built in Q3 [4]

Industry Overview - The cannabis industry is experiencing growth and progress, with expectations for continued development into 2026 despite recent downtrends in stock performance [1][2] - The repeal of the 2018 Farm Bill is anticipated to significantly impact the hemp market and could lead to federal legalization of cannabis, providing a more structured framework for the industry in the United States [2][3] Company Highlights - **FLUENT Corp.** is expanding its operations by opening a new dispensary in Brandon, Florida, as part of its strategy to optimize its retail footprint in high-demand markets [5][6] - The company emphasizes a disciplined growth approach, focusing on high-performing markets to enhance service and operational performance [6] - **Ayr Wellness Inc.** has initiated proceedings under the Companies' Creditors Arrangement Act in Canada as part of its restructuring process, transitioning core assets to a new acquisition vehicle owned by senior noteholders [8][9] - **Planet 13 Holdings Inc.** has announced a partnership with Praetorian Global, Inc. to launch ONI products exclusively in its Florida stores, aligning with its commitment to high-quality cannabis offerings [12]

Core Insights - Cresco Labs (CRLBF) has announced its entry into the German market, marking its first expansion outside the United States, which indicates a strategic shift from its previous dependence on the domestic cannabis market [1][8] Group 1: Strategic Expansion - The entry into Germany is significant as the U.S. cannabis market is saturated and highly regulated, while Germany is the largest medical cannabis market in Europe, valued at over €670 million and expected to double in the next four years [2][4] - Cresco has partnered with Blossom, a EU GMP-certified manufacturer in Portugal, to produce three signature flower SKUs for distribution through licensed pharmacies in Germany, ensuring compliance with European quality standards [3][4] - This expansion allows Cresco to tap into a higher-margin, prescription-driven revenue stream in a centrally regulated system, providing more stability compared to many U.S. states [4][5] Group 2: Domestic Challenges - Prior to the German expansion, Cresco's revenues were entirely generated from the U.S., making it vulnerable to challenges in a heavily regulated and price-compressed domestic market, with Q3 2025 revenues falling 8% year over year to $165 million [6][8] - The company anticipates Q4 revenues to remain unchanged sequentially, reflecting ongoing pricing declines, and both gross and EBITDA margins are under pressure due to weaker pricing and increased competition [7][8] Group 3: Competitive Landscape - Cresco faces intense competition in the cannabis market from companies like Canopy Growth, Curaleaf Holdings, and Tilray Brands, which are also pursuing international expansion strategies [9][10] - As Cresco establishes its presence in Europe, it may attract increased attention from competitors, potentially leading to more aggressive strategies and sector consolidation [10] Group 4: Stock Performance and Outlook - Cresco's stock has underperformed the industry year to date, and loss per share estimates for 2025 and 2026 have widened over the past month [11][13] - While the move into Germany is a positive strategic shift, it is unlikely to significantly impact revenues in the short term, leaving the company exposed to ongoing U.S. market challenges [14][15]